Title:
POLYPEPTIDES
Document Type and Number:
WIPO Patent Application WO/2020/127376
Kind Code:
A3
Abstract:
The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD40, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.
Inventors:
DERONIC ADNAN (SE)
CARLSSON FREDRIKA (SE)
HÄGERBRAND KARIN (SE)
VON SCHANTZ LAURA (SE)
SÄLL ANNA (SE)
ELLMARK PETER (SE)
CARLSSON FREDRIKA (SE)
HÄGERBRAND KARIN (SE)
VON SCHANTZ LAURA (SE)
SÄLL ANNA (SE)
ELLMARK PETER (SE)
Application Number:
PCT/EP2019/085789
Publication Date:
August 06, 2020
Filing Date:
December 17, 2019
Export Citation:
Assignee:
ALLIGATOR BIOSCIENCE AB (SE)
International Classes:
C07K16/28; A61K39/00; A61P35/00; C07K16/30; C07K16/32
Domestic Patent References:
| WO2018220216A1 | 2018-12-06 | |||
| WO2015181805A1 | 2015-12-03 | |||
| WO2018158719A1 | 2018-09-07 | |||
| WO2019093342A1 | 2019-05-16 |
Foreign References:
| US20180194862A1 | 2018-07-12 |
Other References:
BUSHRA HUSAIN ET AL: "Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies", BIODRUGS, vol. 32, no. 5, 21 August 2018 (2018-08-21), NZ, pages 441 - 464, XP055678494, ISSN: 1173-8804, DOI: 10.1007/s40259-018-0299-9
ANONYMOUS: "AbbVie R&D Day Forward-Looking Statements and Non-GAAP Financial Information", 1 January 2016 (2016-01-01), XP055678496, Retrieved from the Internet [retrieved on 20200322]
E DAHLEN ET AL: "Therapeutic Advances in Vaccines and Immunotherapy Bispecific antibodies in cancer immunotherapy", THERAPEUTIC ADVANCES IN VACCINES AND IMMUNOTHERAPY, 1 March 2018 (2018-03-01), pages 3 - 17, XP055678495, Retrieved from the Internet [retrieved on 20200322], DOI: 10.1177/2515135518763280Therapeutic
HEATHER A. COOKE ET AL: "EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies", MABS, vol. 10, no. 8, 20 September 2018 (2018-09-20), US, pages 1248 - 1259, XP055680155, ISSN: 1942-0862, DOI: 10.1080/19420862.2018.1519631
STERN PETER L ET AL: "5T4 oncofoetal antigen: an attractive target for immune intervention in cancer", CANCER IMMUNOLOGY, IMMUNOTHERAPY, NIH AUTHOR MANUSCRIPT, SPRINGER, BERLIN/HEIDELBERG, vol. 66, no. 4, 18 October 2016 (2016-10-18), pages 415 - 426, XP036192305, ISSN: 0340-7004, [retrieved on 20161018], DOI: 10.1007/S00262-016-1917-3
SHIRIN EYVAZI ET AL: "Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update", CURRENT CANCER DRUG TARGETS, vol. 18, no. 9, 17 October 2018 (2018-10-17), NL, pages 857 - 868, XP055708279, ISSN: 1568-0096, DOI: 10.2174/1568009618666180102102311
ANONYMOUS: "AbbVie R&D Day Forward-Looking Statements and Non-GAAP Financial Information", 1 January 2016 (2016-01-01), XP055678496, Retrieved from the Internet
E DAHLEN ET AL: "Therapeutic Advances in Vaccines and Immunotherapy Bispecific antibodies in cancer immunotherapy", THERAPEUTIC ADVANCES IN VACCINES AND IMMUNOTHERAPY, 1 March 2018 (2018-03-01), pages 3 - 17, XP055678495, Retrieved from the Internet
HEATHER A. COOKE ET AL: "EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies", MABS, vol. 10, no. 8, 20 September 2018 (2018-09-20), US, pages 1248 - 1259, XP055680155, ISSN: 1942-0862, DOI: 10.1080/19420862.2018.1519631
STERN PETER L ET AL: "5T4 oncofoetal antigen: an attractive target for immune intervention in cancer", CANCER IMMUNOLOGY, IMMUNOTHERAPY, NIH AUTHOR MANUSCRIPT, SPRINGER, BERLIN/HEIDELBERG, vol. 66, no. 4, 18 October 2016 (2016-10-18), pages 415 - 426, XP036192305, ISSN: 0340-7004, [retrieved on 20161018], DOI: 10.1007/S00262-016-1917-3
SHIRIN EYVAZI ET AL: "Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update", CURRENT CANCER DRUG TARGETS, vol. 18, no. 9, 17 October 2018 (2018-10-17), NL, pages 857 - 868, XP055708279, ISSN: 1568-0096, DOI: 10.2174/1568009618666180102102311
Attorney, Agent or Firm:
SMITH, Stephen Edward (GB)
Download PDF: